CLSA’s federal government relations team provides an update on the outlook for key federal life sciences legislation likely to be addressed this year in Congress.
This August, CLSA participated in a medical technology industry roundtable discussion with Congressman Khanna (D-Fremont). Organized by AdvaMed and hosted by BD Biosciences in San Jose, attendees included representatives from CLSA members BD and Roche, and other medtech innovators including Boston Scientific, Elekta, Stryker and Varian.
In early August, CLSA organized a 2-day tour of multiple life sciences sector companies and research institutions across the Bay Area for Congressman Tony Cárdenas (D-San Fernando Valley), and his Washington DC-based staff. Cárdenas and our CLSA Federal Government Relations team visited & toured regional CLSA member companies including: Sutro Biopharma (San Carlos), 23andMe (Mountain View), Johnson & Johnson Innovation | JLABS (South San Francisco), and BioMarin (San Rafael and Novato).
Today, CLSA applauded the U.S. House passage of H.R. 184, the Protect Medical Innovation Act, which permanently repeals the job and innovation hindering 2.3% medical device excise tax levied on medical technology companies.
CLSA Board Member David Beier pens an op-ed in STAT News regarding the impact of the 2.3% medical device tax on patient care and innovation.
With the 2018 midterms elections only months away, the California Congressional delegation will soon be welcoming their newest members in the 116th Congress. Since the California Primary Elections in June, CLSA has held three meet and greets with Congressional Candidates: Diane Harkey, Mike Levin and Young Kim.
CLSA is proud to endorse the Ensuring Patient Access to Critical Breakthrough Products Act (H.R. 5997), bipartisan legislation that bridges Medicare patient access gaps and modernizes policies to allow coverage of medical technologies approved through FDA’s expedited review process.
As results from yesterday’s California Primary Elections continue trickling in, the CLSA federal government relations team would like to share a brief update on some anticipated changes in the makeup of our California delegation for the 117th Congress, and offer additional details on several key California congressional races you may be interested in.
The FDA recently launched an “Innovation Challenge” intended to spur the development of medical devices to help combat the opioid crisis and achieve the goal of preventing and treating opioid use disorder.
Despite media and policymaker scrutiny over the cost of prescription drugs, the healthcare companies making the most money are not biopharmaceutical innovators. Check out CLSA’s infographic calling for more accountability of Pharmacy Benefit Managers (PBMs).